In this Issue:
Afatinib prolongs survival in advanced lung cancer
Crizotinib in advanced ALK+ non-squamous NSCLC
Alectinib in crizotinib pre-treated ALK-rearranged NSCLC
Pembrolizumab active in advanced NSCLC
High-dose hemithoracic RT for mesothelioma?
Neoadjuvant chemoradiation in stage IIIA/N2 NSCLC
MAGE-A3 cancer immunotherapy in resected NSCLC
Treating NSCLC with acquired resistance to gefitinib
Continuing erlotinib beyond RECIST PD is feasible
Dabrafenib active in NSCLC with BRAF mutations
Please login below to download this issue (PDF)